| Market Cap | 0.95B | P/E | - | EPS this Y | 55.10% | Ern Qtrly Grth | - |
| Income | -109.16M | Forward P/E | 191.69 | EPS next Y | 54.20% | 50D Avg Chg | -7.00% |
| Sales | 264.38M | PEG | - | EPS past 5Y | - | 200D Avg Chg | 6.00% |
| Dividend | N/A | Price/Book | 6.71 | EPS next 5Y | - | 52W High Chg | -18.00% |
| Recommedations | 1.50 | Quick Ratio | 3.02 | Shares Outstanding | 47.71M | 52W Low Chg | 44.00% |
| Insider Own | 2.21% | ROA | -12.27% | Shares Float | 35.91M | Beta | 1.15 |
| Inst Own | 118.08% | ROE | -70.98% | Shares Shorted/Prior | 7.05M/6.87M | Price | 24.92 |
| Gross Margin | 72.27% | Profit Margin | -41.29% | Avg. Volume | 536,962 | Target Price | 61.30 |
| Oper. Margin | -31.12% | Earnings Date | Oct 31 | Volume | 465,877 | Change | -0.20% |
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.
| Cantor Fitzgerald | Overweight | Aug 8, 24 |
| Evercore ISI Group | Outperform | Aug 8, 24 |
| Baird | Outperform | Aug 8, 24 |
| HC Wainwright & Co. | Buy | Jul 26, 24 |
| HC Wainwright & Co. | Buy | Jul 8, 24 |
| HC Wainwright & Co. | Buy | Jun 28, 24 |
| Stifel | Buy | Jun 20, 24 |
| Citigroup | Buy | Jun 18, 24 |
| JP Morgan | Overweight | Jun 18, 24 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Vig Pamela | CHIEF SCIENTIFIC OFF.. CHIEF SCIENTIFIC OFFICER | Feb 02 | Sell | 26.1918 | 1,214 | 31,797 | 28,691 | 02/05/24 |
| Longpre Lara | CHIEF DEVELOPMENT OF.. CHIEF DEVELOPMENT OFFICER | Feb 02 | Sell | 26.1918 | 847 | 22,184 | 104,407 | 02/05/24 |
| Radovich Peter | PRESIDENT AND COO PRESIDENT AND COO | Feb 02 | Sell | 26.1917 | 1,790 | 46,883 | 34,695 | 02/05/24 |
| Peetz Christopher | CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER | Feb 02 | Sell | 26.1918 | 6,013 | 157,491 | 104,112 | 02/05/24 |
| Howe Jolanda | SVP, GLOBAL CONTROLL.. SVP, GLOBAL CONTROLLER | Jan 31 | Sell | 26.19 | 735 | 19,250 | 1,759 | 02/02/24 |
| Radovich Peter | CHIEF OPERATING OFFI.. CHIEF OPERATING OFFICER | Jan 08 | Sell | 28.0345 | 1,408 | 39,473 | 36,485 | 01/09/24 |
| Longpre Lara | CHIEF DEVELOPMENT OF.. CHIEF DEVELOPMENT OFFICER | Jan 08 | Sell | 28.0350 | 1,019 | 28,568 | 105,254 | 01/09/24 |
| Vig Pamela | HEAD OF RESEARCH & D.. HEAD OF RESEARCH & DEVELOPMENT | Jan 08 | Sell | 28.0343 | 1,408 | 39,472 | 29,905 | 01/09/24 |
| Peetz Christopher | PRESIDENT AND CEO PRESIDENT AND CEO | Jan 08 | Sell | 28.0348 | 5,209 | 146,033 | 110,125 | 01/09/24 |
| Howe Jolanda | SVP, GLOBAL CONTROLL.. SVP, GLOBAL CONTROLLER | Jan 06 | Sell | 28.04 | 528 | 14,805 | 722 | 01/09/24 |
| Howe Jolanda | SVP, Global Controll.. SVP, Global Controller | Dec 05 | Option | 2.94 | 2,500 | 7,350 | 2,500 | 12/06/23 |
| Howe Jolanda | SVP, Global Controll.. SVP, Global Controller | Dec 05 | Sell | 32.4 | 2,500 | 81,000 | 12/06/23 | |
| GREY MICHAEL G | Director Director | Sep 13 | Sell | 32 | 14,608 | 467,456 | 09/14/23 | |
| GREY MICHAEL G | Director Director | Sep 13 | Option | 2.94 | 14,608 | 42,948 | 14,216 | 09/14/23 |
| BJERKHOLT ERIC | Chief Financial Offi.. Chief Financial Officer | Sep 11 | Buy | 29.6492 | 10,000 | 296,492 | 10,000 | 09/12/23 |
| Heron Patrick J | Director Director | Aug 31 | Buy | 26.25 | 147,991 | 3,884,764 | 147,991 | 09/05/23 |
| Radovich Peter | Chief Operating Offi.. Chief Operating Officer | Jul 03 | Sell | 25.6466 | 1,425 | 36,546 | 37,675 | 07/05/23 |
| Longpre Lara | Chief Development Of.. Chief Development Officer | Jul 03 | Sell | 25.6466 | 1,004 | 25,749 | 105,839 | 07/05/23 |
| GREY MICHAEL G | Director Director | May 03 | Sell | 28 | 14,608 | 409,024 | 05/04/23 | |
| GREY MICHAEL G | Director Director | May 03 | Option | 2.94 | 14,608 | 42,948 | 14,608 | 05/04/23 |
| O'Donnell Niall | Director Director | Nov 11 | Sell | 19.76 | 300,000 | 5,928,000 | 1,621,118 | 11/15/22 |
| Flynn James E | - - | Jun 06 | Sell | 24.95 | 38,478 | 960,026 | 1,540,190 | 06/08/22 |
| Clements Ian | Chief Financial Offi.. Chief Financial Officer | Nov 24 | Buy | 14.15 | 1,450 | 20,518 | 18,561 | 11/29/21 |